Investigational drug · Phase 3
HRS-2129
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Gouty Arthritis, Postoperative Analgesia, Postoperative Pain in Orthopaedics.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
7
Any phase or sponsor naming "HRS-2129"
First trial start
2025
Mar 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-2129", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Gouty Arthritis
- Postoperative Analgesia
- Postoperative Pain in Orthopaedics
Approved drugs for the same conditions: Gout · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-2129" as an intervention, largest first.
- A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee OsteoarthritisPivotal-lookingCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07351968 · 202 participants · Start Mar 10, 2026 · Primary completion Jul 17, 2026
Drug: HRS-2129 Tablet; Celecoxib capsule and 2 more · For: Moderate Pain in Knee Osteoarthritis; Severe Pain in Knee Osteoarthritis
Sites: Nanjing, China
- Clinical Study of HRS-2129 for Postoperative Analgesia in OrthopaedicsPivotal-lookingCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06780267 · 199 participants · Start Mar 11, 2025 · Primary completion Mar 19, 2026
Drug: HRS-2129; HRS-2129 placebo and 1 more · For: Postoperative Pain in Orthopaedics
Sites: Chengdu, China
- A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic PainPivotal-lookingRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07377721 · 168 participants (planned) · Start Mar 24, 2026 · Primary completion Sep 2026
Drug: HRS-2129 Tablets; HRS-2129 Placebo and 2 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Beijing, China; Chongqing, China
- A Phase Ⅱ/Ⅲ Study of HRS-2129 for Postsurgical Pain Management in Abdominal SurgeryPivotal-lookingCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07185594 · 156 participants · Start Oct 24, 2025 · Primary completion Dec 31, 2025
Drug: HRS-2129 Tablets; Blank Preparation. and 1 more · For: Postoperative Analgesia
Sites: Zhengzhou, China; Hangzhou, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07706777 · 90 participants (planned) · Start Aug 19, 2026 · Primary completion Oct 2026
Drug: HRS-2129 Tablet; HRS-2129 Tablet and 1 more · For: Acute Gouty Arthritis
Sites: Guangzhou, China; Nanjing, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06619392 · 44 participants · Start Oct 17, 2024 · Primary completion Jan 20, 2025
Drug: HRS-2129; HRS-2129 Placebo · For: Pain
Sites: Changsha, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06742840 · 23 participants · Start Dec 30, 2024 · Primary completion Jul 2, 2025
Drug: HRS-2129; HRS-2129 placebo · For: Pain
Sites: Changsha, China
Newest research
PubMed records naming it or its code names, newest first.
- First-in-Human Phase I Trial of HRS-2129, a Selective Nav1.8 Inhibitor: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects.
Huang J, Wu Q, Wang S, et al. · Drug Des Devel Ther 2026
Also in development for Acute Gouty Arthritis
- PlonmarlimabPhase 33 trials
TJ Biopharma Co., Ltd. · Acute Gouty Arthritis, Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytoses
- ABP-745Phase 22 trials
Atom Therapeutics Co., Ltd · Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.